UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial

Diabetes care, 2018-10, Vol.41 (10), p.2147-2154

2018

Volltextzugriff (PDF)

C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective

Diabetes, obesity & metabolism, 2022-10, Vol.24 (10), p.1912-1926

2022

Volltextzugriff (PDF)

Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes

Diabetes care, 2013-12, Vol.36 (12), p.3860-3862

2013

Volltextzugriff (PDF)

The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications

Diabetes, obesity & metabolism, 2020-05, Vol.22 (5), p.743-754

2020

Volltextzugriff (PDF)

Hypoglycemia, Diabetes, and Cardiovascular Events

Diabetes care, 2010-06, Vol.33 (6), p.1389-1394

2010

Volltextzugriff (PDF)

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)

Diabetes care, 2014-10, Vol.37 (10), p.2755-2762

2014

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of basal insulins

Diabetes technology & therapeutics, 2011-06, Vol.13 Suppl 1 (S1), p.S15-S-24

2011

Volltextzugriff (PDF)

John E. Gerich: Father of Modern Physiology of Glucose Homeostasis, Counterregulation to Hypoglycemia, and Mechanistic Treatment of Diabetes

Diabetes care, 2018-10, Vol.41 (10), p.2059-2063

Bolli, Geremia B

2018

Volltextzugriff (PDF)

Insulin is Required for Prandial Ghrelin Suppression in Humans

Diabetes (New York, N.Y.), 2003-12, Vol.52 (12), p.2923-2927

2003

Volltextzugriff (PDF)

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

Diabetes care, 2015-12, Vol.38 (12), p.2217-2225

2015

Volltextzugriff (PDF)

Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage

Diabetes (New York, N.Y.), 2023-10, Vol.72 (10), p.1364-1373

2023

Volltextzugriff (PDF)

Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin

Diabetes care, 2020-10, Vol.43 (10), p.2333-2335

2020

Volltextzugriff (PDF)

Insulin Centennial: Milestones influencing the development of insulin preparations since 1922

Diabetes, obesity & metabolism, 2022-01, Vol.24 (S1), p.27-42

2022

Volltextzugriff (PDF)

Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial

Diabetes, obesity & metabolism, 2024-02, Vol.26 (2), p.503-511

2024

Volltextzugriff (PDF)

The physiological basis of insulin therapy in people with diabetes mellitus

Diabetes research and clinical practice, 2021-05, Vol.175, p.108839-108839, Article 108839

2021

Volltextzugriff (PDF)

A comparison of the effectiveness and safety of insulin glargine 300 U/ml versus 100 U/ml in children and adolescents with newly diagnosed type 1 diabetes: A retrospective, observational, short‐term study

Diabetes, obesity & metabolism, 2022-12, Vol.24 (12), p.2474-2477

2022

Volltextzugriff (PDF)

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial

Diabetes care, 2013-03, Vol.36 (3), p.498-504

2013

Volltextzugriff (PDF)

Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials

Diabetes, obesity & metabolism, 2020-10, Vol.22 (10), p.1880-1885

2020

Volltextzugriff (PDF)

Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136

Diabetes care, 2021-03, Vol.44 (3), p.e59-e60

2021

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

Diabetes care, 2019-01, Vol.42 (1), p.85-92

2019

Volltextzugriff (PDF)

Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs

Diabetes, obesity & metabolism, 2021-01, Vol.23 (1), p.166-174

2021

Volltextzugriff (PDF)

Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial

JACC. Heart failure, 2018-01, Vol.6 (1), p.8-17

2018

Volltextzugriff (PDF)

A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study

Diabetes care, 2018-08, Vol.41 (8), p.1672-1680

2018

Volltextzugriff (PDF)

The role of gastric emptying in glucose homeostasis and defense against hypoglycemia: Innocent bystander or partner in crime?

Diabetes research and clinical practice, 2023-09, Vol.203, p.110828-110828, Article 110828

2023

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection

Diabetes care, 2015-12, Vol.38 (12), p.2204-2210

2015

Volltextzugriff (PDF)

1 – 25 von 216

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(175)
Mit Volltextzugriff
(161)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(121)
Science & Technology
(121)
Life Sciences & Biomedicine
(120)
Endocrinology & Metabolism
(105)
Insulin
(78)
Diabetes
(75)
Male
(74)
Female
(67)
Biological And Medical Sciences
(59)
Adult
(58)
Hypoglycemia
(55)
Medical Sciences
(55)
Blood Glucose - Metabolism
(51)
Diabetes Mellitus, Type 1 - Drug Therapy
(43)
Endocrinopathies
(42)
Endocrine Pancreas. Apud Cells
(41)
Diabetes Mellitus
(40)
Insulin - Administration & Dosage
(40)
Diabetes. Impaired Glucose Tolerance
(39)
Insulin - Blood
(39)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial

C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective

Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes

The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications

Hypoglycemia, Diabetes, and Cardiovascular Events

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)

Pharmacokinetics and pharmacodynamics of basal insulins

John E. Gerich: Father of Modern Physiology of Glucose Homeostasis, Counterregulation to Hypoglycemia, and Mechanistic Treatment of Diabetes

Insulin is Required for Prandial Ghrelin Suppression in Humans

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage

Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin

Insulin Centennial: Milestones influencing the development of insulin preparations since 1922

Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial

The physiological basis of insulin therapy in people with diabetes mellitus

A comparison of the effectiveness and safety of insulin glargine 300 U/ml versus 100 U/ml in children and adolescents with newly diagnosed type 1 diabetes: A retrospective, observational, short‐term study

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial

Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials

Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs

Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial

A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study

The role of gastric emptying in glucose homeostasis and defense against hypoglycemia: Innocent bystander or partner in crime?

Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection

Suchergebnisse filtern